EUVIMEDEUVIMED entdecken
Leserbrief

Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”

William F Fearon iD, Kuniaki Takahashi, Kiran K Khush iD

Circulation · 04.08.2026 · 154 (5)

DOI: 10.1161/circulationaha.126.080757 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Circulation, erschienen am 04.08.2026. Verfasst von William F Fearon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA, (W.F.F., K.T., K.K.K.). Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University, CA, (W.F.F., K.T., K.K.K.).
  • VA Palo Alto Health Care System, CA (W.F.F.).

ORCID-Profile: William F Fearon, Kiran K Khush

Zitieren

APA

Fearon, W. F., Takahashi, K., & Khush, K. K. (2026). Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”. Circulation, 154(5). https://doi.org/10.1161/circulationaha.126.080757

Vancouver

Fearon WF, Takahashi K, Khush KK. Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”. Circulation. 2026;154(5). doi:10.1161/circulationaha.126.080757

BibTeX
@article{Fearon2026,
  author = {Fearon, William F and Takahashi, Kuniaki and Khush, Kiran K},
  title = {Response by Fearon et al to Letter Regarding Article, “Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial”},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {5},
  doi = {10.1161/circulationaha.126.080757}
}
Kostenlos starten →